Condition: Graves Disease · Sponsor: Merida Biosciences
The purpose of this study is to evaluate how well MER511 is tolerated and what side effects may occur in adults who have Graves' disease. The study drug will be administered either intravenously (into a vein in the arm) or subcutaneously (under the skin). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
This description comes directly from the study's public registry record.
Clinical Operations · +1 339-255-3030 · clinicaltrials@meridabio.com
Always discuss trial participation with your own doctor first.
| Site # 1103 | Phoenix, Arizona, United States | Withdrawn |
| Site # 1101 | Hollywood, Florida, United States | Recruiting |
| Site # 1112 | Miami, Florida, United States | Recruiting |
| Site # 1109 | Wesley Chapel, Florida, United States | Recruiting |
| Site # 1107 | Boston, Massachusetts, United States | Recruiting |
| Site # 1102 | Rochester, Minnesota, United States | Recruiting |
| Site # 1104 | Columbus, Ohio, United States | Recruiting |
| Site # 1108 | Philadelphia, Pennsylvania, United States | Recruiting |
| Site # 1105 | Webster, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07305818